HC Wainwright Issues Optimistic Outlook for CRDF Earnings

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Investment analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for Cardiff Oncology in a report released on Wednesday, February 25th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.12) per share for the quarter, up from their previous forecast of ($0.16). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Cardiff Oncology’s Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.49) EPS.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.07. The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.13 million. Cardiff Oncology had a negative return on equity of 82.01% and a negative net margin of 7,733.22%.

Several other equities analysts have also recently issued reports on CRDF. Noble Financial started coverage on shares of Cardiff Oncology in a research note on Monday, January 5th. They issued an “outperform” rating and a $12.00 price objective on the stock. Piper Sandler decreased their price target on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.10.

Cardiff Oncology Stock Down 1.0%

NASDAQ:CRDF opened at $1.94 on Friday. The business’s 50-day moving average price is $2.32 and its 200 day moving average price is $2.25. Cardiff Oncology has a 52-week low of $1.48 and a 52-week high of $4.56. The firm has a market cap of $132.62 million, a P/E ratio of -2.81 and a beta of 1.33.

Hedge Funds Weigh In On Cardiff Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Laurion Capital Management LP raised its stake in Cardiff Oncology by 7.3% during the 4th quarter. Laurion Capital Management LP now owns 2,646,738 shares of the company’s stock valued at $7,437,000 after purchasing an additional 180,866 shares during the period. Acorn Capital Advisors LLC raised its position in Cardiff Oncology by 39.3% during the third quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after buying an additional 553,317 shares during the period. Geode Capital Management LLC raised its position in Cardiff Oncology by 7.5% during the second quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock valued at $4,723,000 after buying an additional 104,409 shares during the period. Franklin Resources Inc. purchased a new stake in Cardiff Oncology in the 4th quarter worth about $3,388,000. Finally, State Street Corp boosted its position in Cardiff Oncology by 4.0% during the 4th quarter. State Street Corp now owns 1,191,647 shares of the company’s stock worth $3,349,000 after acquiring an additional 45,288 shares during the period. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology News Roundup

Here are the key news stories impacting Cardiff Oncology this week:

• Positive Sentiment: HC Wainwright raised quarterly and full‑year EPS forecasts and reiterated a Buy rating with a $10 price target — the firm increased Q1–Q4 2026 and FY2026 EPS estimates (FY now -$0.49 versus prior -$0.64), reflecting a less‑negative earnings outlook that can support upside. HC Wainwright research notes / MarketBeat
• Positive Sentiment: Company announced management will participate in three investor conferences in March — added investor access and upcoming presentations can improve visibility and drive short‑term buying interest. Cardiff Oncology to Participate in Three Upcoming Investor Conferences
• Neutral Sentiment: Coverage pieces and news summaries (e.g., AAII) reported a prior intraday rally (~+10%) that appears linked to the HC Wainwright chatter and conference news — media attention can amplify short‑term volatility but doesn’t change fundamentals by itself. Why Cardiff Oncology’s (CRDF) Stock Is Up 10.01%
• Negative Sentiment: Piper Sandler cut its price target to $6.00 — a lower target from another sell‑side firm increases mixed messaging and can weigh on sentiment, limiting upside from the HC Wainwright call. Piper Sandler Lowers Cardiff Oncology Price Target to $6.00
• Neutral Sentiment: Reported short‑interest data in the filings is effectively meaningless/noisy (shows 0 shares and NaN changes) — no clear short squeeze signal from the published short interest. (Likely not a material factor until reliable short‑interest figures appear.)

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.